Experience

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million public offering of common stock by Personalis, Inc. The common stock…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its common stock for up to an aggregate amount of $50 million. Based in…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million. Atreca is a…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public offering of ordinary shares of Horizon Therapeutics Public Limited…

Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock for an aggregate price to the public of approximately $170 million…

Davis Polk advised the joint book running managers in connection with the $377.3 million initial public offering of 17,968,750 shares of common stock of Oak Street Health, Inc., which…

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…